

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Prevention strategy, fungal infections, WHO updates on Omicron

Peer reviewed journals featured:

- A randomised controlled trial of the effect of a prevention strategy (which included antigen-screening within 3 days, mask wearing, and optimised ventilation) on SARS-CoV-2 transmission [here](#)
- Observational studies on:
 - Fungal infections in mechanically ventilated COVID-19 patients [here](#)
 - Impact of Delta on incubation, transmission settings and vaccine effectiveness [here](#)
 - Effectiveness of Vaxzevria (AstraZeneca) vaccine during the Delta surge in India [here](#)
- An editorial on indoor ventilation during COVID-19 [here](#)
- Commentary on:
 - The social identity of post-acute COVID-19 syndrome [here](#)
 - Benefit-harm analysis in “no jab, no job” approaches [here](#)

Letters and correspondence discussed:

- Oral anti-COVID-19 drugs in the post-vaccine era [here](#)
- Short-term inflammatory musculoskeletal manifestations after COVID-19 vaccines [here](#)

Pre-peer review articles featured:

- Anti-spike monoclonal antibody therapy in pregnant women with mild to moderate COVID-19 [here](#)
- Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection [here](#)

Guidance and reports

- The World Health Organization published updates on Omicron [here](#) and its COVID-19 tracker [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)
- The Therapeutic Goods Administration (TGA) released information on international COVID-19 vaccines recognised by Australia [here](#)